知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

782 条记录 (耗时 0.033 秒)

    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PEPTIDE TREATMENT
    91.
    发明申请
    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PEPTIDE TREATMENT 有权
    药物组合物和肽治疗方法

    公开(公告)号：US20100009921A1

    公开(公告)日：2010-01-14

    申请号：US12562974

    申请日：2009-09-18

    申请人： Robert J. Gyurik ,  Carl Reppucci

    发明人： Robert J. Gyurik ,  Carl Reppucci

    IPC分类号： A61K38/00 ,  A61K38/10

    CPC分类号： A61K9/0043 ,  A61K9/08 ,  A61K9/107 ,  A61K9/1075 ,  A61K31/12 ,  A61K31/365 ,  A61K31/485 ,  A61K38/02 ,  A61K38/08 ,  A61K38/25 ,  A61K47/06 ,  A61K47/08 ,  A61K47/10 ,  A61K47/18 ,  A61K47/186 ,  A61K47/22 ,  A61K47/32 ,  A61K47/44 ,  Y10S514/937

    摘要： Disclosed are compositions and methods for treating a patient with a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins, wherein the pharmaceutical composition is in the form of an emulsified nasal spray comprising: a macrocyclic permeation enhancer, a liquid carrier comprising water, and a therapeutically effective amount of a pharmaceutically active agent other than insulin selected from the group consisting of peptides, peptidomimetics, and proteins; wherein the macrocyclic permeation enhancer is a Hsieh enhancer emulsified in the liquid carrier; and wherein the Hsieh enhancer has the following structure: wherein X and Y are oxygen, sulfur or an imino group of the structure or ═N—R with the proviso that when Y is the imino group, X is an imino group, and when Y is sulfur, X is sulfur or an imino group, A is a group having the structure wherein X and Y are defined above, m and n are integers having a value from 1 to 20 and the sum of m+n is not greater than 25, p is an integer having a value of 0 or 1, q is an integer having a value of 0 or 1, r is an integer having a value of 0 or 1, and each of R, R1, R2, R3, R4, R5 and R6 is independently hydrogen or an alkyl group having from 1 to 6 carbon atoms which may be straight chained or branched provided that only one of R1 to R6 can be an alkyl group, with the proviso that when p, q and r have a value of 0 and Y is oxygen, m+n is at least 11, and with the further proviso that when X is an imino group, q is equal to 1, Y is oxygen, and p and r are 0, then m+n is at least 11.

    摘要翻译： 公开了用除了选自肽，肽模拟物和蛋白质的胰岛素以外的药物活性剂治疗患者的组合物和方法，其中所述药物组合物为乳化鼻喷雾剂的形式，其包含：大环渗透促进剂， 包含水的液体载体和治疗有效量的选自肽，肽模拟物和蛋白质的胰岛素以外的药学活性剂; 其中所述大环渗透促进剂是在所述液体载体中乳化的Hsieh增强剂; 并且其中所述Hsieh增强剂具有以下结构：其中X和Y是结构中的氧，硫或亚氨基或-NR，条件是当Y是亚氨基时，X是亚氨基，当Y是硫时 X是硫或亚氨基，A是具有以上结构的基团，其中X和Y定义如上，m和n是具有1至20的整数，并且m + n的总和不大于25，p 是0或1的整数，q是0或1的整数，r是0或1的整数，R，R1，R2，R3，R4，R5和 R6独立地是氢或具有1至6个碳原子的烷基，其可以是直链或支链的，只要R1至R6中只有一个可以是烷基，条件是当p，q和r的值为 0和Y是氧，m + n至少为11，另外条件是当X是亚氨基时，q等于1，Y是氧，p和r是0，则m + n在 至少11。

    Pharmaceutical composition
    94.
    发明授权
    Pharmaceutical composition 有权

    公开(公告)号：US07608609B2

    公开(公告)日：2009-10-27

    申请号：US12359183

    申请日：2009-01-23

    申请人： Robert J. Gyurik

    发明人： Robert J. Gyurik

    IPC分类号： A01N45/00

    CPC分类号： A61K31/568 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/56 ,  A61K31/57 ,  A61K47/08 ,  A61K47/10 ,  A61K47/22 ,  A61K47/32

    摘要： A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.

    Pharmaceutical composition
    95.
    发明授权
    Pharmaceutical composition 有权

    公开(公告)号：US07608607B2

    公开(公告)日：2009-10-27

    申请号：US12356943

    申请日：2009-01-21

    申请人： Robert J. Gyurik

    发明人： Robert J. Gyurik

    IPC分类号： A01N45/00

    CPC分类号： A61K31/568 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/56 ,  A61K31/57 ,  A61K47/08 ,  A61K47/10 ,  A61K47/22 ,  A61K47/32

    摘要： A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.

    TOPICAL COMPOSITIONS
    96.
    发明申请
    TOPICAL COMPOSITIONS 有权
    主题组成

    公开(公告)号：US20090247529A1

    公开(公告)日：2009-10-01

    申请号：US12304420

    申请日：2007-06-14

    申请人： Ake Lindahl ,  Birgitta Svensson ,  Anna Holmberg ,  Johan Engblom

    发明人： Ake Lindahl ,  Birgitta Svensson ,  Anna Holmberg ,  Johan Engblom

    IPC分类号： A61K31/5375 ,  A61K47/12 ,  A61K47/30 ,  A61K47/38 ,  A61K31/13 ,  A61K31/135 ,  A61K31/522 ,  A61P31/10

    CPC分类号： A61K47/10 ,  A61K9/0014 ,  A61K9/7015 ,  A61K31/137 ,  A61K47/02 ,  A61K47/08 ,  A61K47/12 ,  A61K47/14 ,  A61K47/36 ,  A61K47/38

    摘要： Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-1 infection or HSV-2 infection are provided.

    摘要翻译： 提供用于局部应用的单相药物组合物，以及试剂盒和使用和给药方法。 组合物包含生物活性剂; 包含至少非聚合结晶抑制剂和成膜剂的递送载体; 和挥发性溶剂; 其中所述生物活性剂在所述组合物中以亚饱和状态存在，所述生物活性剂以过饱和状态存在于所述递送载体中，所述结晶抑制剂能够延迟所述递送载体中所述生物活性剂的结晶。 生物活性剂包括特比萘芬和阿昔洛韦。 提供甲真菌病和水痘带状疱疹感染，HSV-1感染或HSV-2感染的治疗。